BRIEF-Merck announces results of study of Relebactam, in combination with Imipenem/Cilastatin

* Phase 2 study of Relebactam, in combination with Imipenem/Cilastatin for complicated urinary tract infections met primary endpoint
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.